![]() BioTech startups and scaleups are working on solutions to make proteomics technologies further standardized and high-throughput. Evosep – Clinical ProteomicsĪdvancements in proteomics allow robust profiling of a large number of clinical samples, particularly for immuno-oncology. The solution serves BioTech companies working on clinical diagnostics, engineered stem cells, and phenotypic screening. The startup’s solution retains the sensitivity and specificity of ELISA while providing scalability to measure 120 secreted proteins at once. The startup develops nELISA, a miniaturized and parallelized version of the enzyme-linked immunoassay (ELISA). Along with improved assays, these solutions often integrate machine learning algorithms.Ĭanadian startup nplex offers a high-throughput proteomics platform for population-wide protein profiling. BioTech startups provide new protein profiling methods that help scale proteomics. As a result, researchers often probe only a few proteins at a time. Moreover, they often miss out on isoforms and post-translational modifications. Traditional techniques for sequencing and quantifying proteins are difficult to scale. The startup’s drug development activities target autoimmune, inflammatory, and neurodegenerative diseases. The biopharmaceutical candidates target the degradation of specific proteins via the proteasome or the autophagosome. Obteron, the startup’s proprietary platform, discovers therapeutic compounds. Proteomics-based technologies and other emerging drug discovery solutions discover drugs that act via methods other than binding to the target protein.Ĭaptor Therapeutics is a Polish BioTech startup targeting the undruggable proteome. Many of these undruggable proteins also play a role in disease development, prompting pharma and BioTech startups to develop solutions that target them. For these proteins, the binding sites are often not known. Captor Therapeutics – Undruggable ProteomeĪ large number of human proteins are inaccessible for current drugs and are collectively called the “undruggable proteome”. The platform also helps pharma and BioTech companies to develop functional proteomic biomarkers for other use cases. This enables healthcare professionals to determine which patients will respond to immunotherapy. QF-Pro, the startup’s biomarker platform, provides a molecular readout of the interaction between T-cells and antigen-presenting cells. Spanish startup Fastbase Solutions leverages proteomics to develop functional diagnostics. Startups are developing functional diagnostics solutions based on proteomics to provide precision medicine. This doesn’t take into account the complexity of subcellular pathways. Current methods mostly compare gene expression before and after the treatment to check the response. Fastbase Solutions – Functional Diagnosticsīiomarkers enable the identification of patients that are likely to benefit from a particular therapeutic intervention. The startup’s solutions help companies to stratify patients based on proteomic data as well as to develop better markers. Using engineered nanoparticles, Seer’s technology enables reproducible and selective binding of proteins for quantitative analysis. The startup’s scalable technology provides unbiased coverage and deep access into the proteome, including for complex samples such as plasma and serum. Seer is a US-based startup that provides solutions for rapid, large-scale proteomics. That is why BioTech startups are working on a range of hardware and software solutions to tap into the benefits of large-scale proteomics. This makes accurate quantification of the proteome incredibly difficult. However, unlike the genome that largely is the same across cells, the proteome differs considerably depending on the cell type and time. ![]() Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.Proteomics provides deep insights into the state of any organism, far surpassing genomic information. ![]() TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. To request a one-on-one meeting with the Captor team, please contact us at or at Captor TherapeuticsĬaptor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. Title: Making the Undruggable, Druggable - The Exciting Potential of Targeted Protein Degradationĭate: Wednesday, 11 th May 2022, 3.10 pm BST / 4.10 pm CEST ![]()
0 Comments
Leave a Reply. |